Welcome to our dedicated page for Lyra Therapeutics news (Ticker: LYRA), a resource for investors and traders seeking the latest updates and insights on Lyra Therapeutics stock.
Lyra Therapeutics, Inc. reports corporate-status, clinical-program and capital-structure developments tied to its LYR-210 program for chronic rhinosinusitis. The company had developed LYR-210 as a bioabsorbable sinonasal implant intended to deliver continuous anti-inflammatory therapy with mometasone furoate, including through the ENLIGHTEN Phase 3 program.
Recent company updates center on the suspension of further LYR-210 development, cost-saving actions, workforce reductions, strategic-alternatives activity, and capital-preservation measures. Earlier updates also covered CRS clinical data, regulatory planning, manufacturing activity, financing, and quarterly operating results.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Lyra Therapeutics, Inc. (Nasdaq: LYRA) has resumed screening and enrollment in its ENLIGHTEN II clinical trial for LYR-210, a bioresorbable nasal implant aimed at treating chronic rhinosinusitis (CRS). The trial targets patients who have not responded to medical management. Resumption of enrollment follows a temporary pause for in-house manufacturing adjustments, which Lyra anticipates will strengthen regulatory compliance. The company is also on track with the first ENLIGHTEN trial, with pivotal results expected in the first half of 2024. Each trial will enroll 180 patients, supporting a New Drug Application to the FDA for LYR-210. The product is designed to provide up to six months of sustained anti-inflammatory treatment, showing promising Phase 2 results with no serious adverse events reported.
Lyra Therapeutics, Inc. (Nasdaq: LYRA) reported its financial results for Q4 and full year 2022, highlighting significant advancements in its clinical trials and production capabilities. The company initiated two Phase 3 trials for LYR-210 aimed at chronic rhinosinusitis (CRS), with completion of enrollment expected by mid-2023. Additionally, data from the Phase 2 BEACON trial for LYR-220 is expected in Q4 2023. The transition to in-house manufacturing is set to enhance product quality and supply. Financially, Lyra recorded a net loss of $55.3 million for 2022, with cash reserves projected to sustain operations through mid-2024.
Lyra Therapeutics (Nasdaq: LYRA) has appointed John Bishop, Ph.D., as the new Chief Technology Officer, effective February 27, 2023. Dr. Bishop will spearhead the scaling-up of manufacturing operations for the company's late-stage product candidates, LYR-210 and LYR-220, designed for chronic rhinosinusitis (CRS). His extensive background in chemistry, manufacturing, and controls in biopharmaceuticals positions him to enhance Lyra's in-house systems. The company has approved an equity grant of 220,000 stock options to Dr. Bishop as part of his employment compensation.
Lyra Therapeutics, Inc. (Nasdaq: LYRA) has completed enrollment in the Phase 2 BEACON trial for LYR-220, targeting chronic rhinosinusitis (CRS) patients post-surgery. This investigational product aims to deliver six months of anti-inflammatory medication through a bioresorbable matrix. Initial results from Part 1 showed a significant 37% improvement in SNOT-22 scores, with no serious adverse events recorded. Topline results from Part 2 are expected in Q4 2023, building on the ongoing development of Lyra's previous candidate, LYR-210, for surgically-naïve CRS patients. These advancements position Lyra favorably in the CRS treatment landscape.
Lyra Therapeutics (NASDAQ: LYRA), a clinical-stage biotechnology company, has announced the issuance of an equity-based award to Gloria Cosgrove, its new Senior Vice President of Quality. This inducement grant includes a non-qualified stock option for 100,000 shares, approved by independent directors, as part of her employment compensation. Lyra is focused on developing therapies for chronic rhinosinusitis (CRS), with two investigational product candidates, LYR-210 and LYR-220, in advanced stages of development. These therapies aim to provide non-surgical treatment options for CRS patients, addressing a significant market need in the U.S.
Lyra Therapeutics (Nasdaq: LYRA) announced that CEO Maria Palasis, Ph.D., will speak at two investor conferences in November 2022. The first event is the Stifel 2022 Healthcare Conference, scheduled for November 15 at 4:10 p.m. ET. The second is the Jefferies London Healthcare Conference, set for November 17 at 4:25 p.m. GMT (11:25 a.m. ET). Webcasts of both presentations will be available on the company's Investor Relations section for 90 days.